Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission

Rheumatology

Volumn 51, Issue 5, 2012, Pages 800-804

  Muro, Yoshinao ^a   Sugiura, Kazumitsu ^a   Hoshino, Kei ^a   Akiyama, Masashi ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Amyopathic dermatomyositis; Anti MDA 5 antibody; Interstitial lung disease; Prognosis

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 ANTIBODY; METHYLPREDNISOLONE; PREDNISOLONE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; AMYOPATHIC DERMATOMYOSITIS; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENETIC TRANSCRIPTION; HUMAN; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; MALE; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; REMISSION; RNA TRANSLATION; SCHOOL CHILD;

ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; DEAD-BOX RNA HELICASES; DERMATOMYOSITIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PROGNOSIS;

EID: 84860235241     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker408     Document Type: Article

References (14)

1. Sato S, Hoshino K, Satoh T et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009;60:2193-200.
2. Kaji K, Fujimoto M, Hasegawa M et al. Identification of a novel autoantibody reactive with 155 and 140kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology 2007;46:25-28.
3. Hoshino K, Muro Y, Sugiura K et al. Anti-MDA5 and anti-TIF1-g antibodies have clinical significance for patients with dermatomyositis. Rheumatology 2010;49: 1726-33.
4. Hamaguchi Y, Kuwana M, Hoshino K et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 2011;147: 391-8.
5. Sato S, Kuwana M. Clinically amyopathic dermatomyositis. Curr Opin Rheumatol 2010;22:639-43.
6. Fiorentino D, Chung L, Zwerner J et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011;65:25-34.
7. Gono T, Kawaguchi Y, Satoh T et al. Clinical manifestation and prognostic factor in anti-melanoma differentiationassociated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology 2010;49:1713-9.
8. Tench CM, Isenberg DA. The variation in anti-ENA characteristics between different ethnic populations with systemic lupus erythematosus over a 10-year period. Lupus 2000;9:374-6.
9. Faria AC, Barcellos KSA, Andrade LEC. Longitudinal fluctuation of antibodies to extractable nuclear antigens in systemic lupus erythematosus. J Rheumatol 2005;32: 1267-72.
10. Marie I, Lahaxa L, Benveniste O et al. Long-term outcome of patients with polymyositis/dermatomyositis and anti-PM-Scl antibody. Br J Dermatol 2010;162:337-44.
11. Bohan A, Peter JB, Bowman RL et al. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine 1977;56:255-86.
12. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sinémyositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002;46:626-36.
13. Kuwana M, Kaburaki J, Mimori T et al. Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 2000;43:1074-84.
14. Barral PM, Morrison JM, Drahos J et al. MDA-5 is cleaved in poliovirus-infected cells. J Virol 2007;81:3677-84.